BioNTech SE (BNTX)
After hours:
| Previous close | 90.15 |
| Open | 89.40 |
| Bid | 89.91 x 200 |
| Ask | 90.12 x 200 |
| Day's range | 88.30 - 90.39 |
| 52-week range | 76.53 - 119.78 |
| Volume | |
| Avg. volume | 658,946 |
| Market cap | 21.385B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings date | 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jun 2022 |
| 1y target est | 111.75 |
GlobeNewswireBioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approache
ZacksFDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
Business WirePfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany, August 22, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the U.S. Food and Drug Administration ("FDA") has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025
